Trial Profile
A phase II trial of a house dust mite allergy immunotherapy in patients hypersensitive to house dust mites.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2012
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy Laboratorios LETI (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.